Use of vaccinal dengue virus doses, for the preparation of a vaccine for inducing protection against dengue virus serotype 4, comprising: a first series of administration of a first dose of vaccinal dengue virus serotype 1 and 2 and a second dose of vaccinal dengue virus serotype 3 and serotype 4； and a second series of administration of the first and second dengue virus doses, which are administrated simultaneously to distinct anatomical sites and the second series is applied at least after 30 days to up to 12 months after the first series, is claimed. Independent claims are included for: (1) a first kit for immunizing against the dengue virus comprising a box containing at least vaccinal dengue virus serotype 1, 2, 3 and 4, in the form of monovalent composition contained in four separate containers or in the form of two bivalent composition contained in two separate containers； (2) a second kit for immunizing against the dengue virus comprising a box containing at least vaccinal dengue virus of first and second serotype in the form of two monovalent composition contained in two separate containers or in the form of a bivalent composition contained in only one container； and (3) a bivalent vaccine comprising a vaccinal dengue virus of the first and a second serotype and a excipient. ACTIVITY : Virucide. MECHANISM OF ACTION : Vaccine. Tests details are described but no results given.
